Brief summary of the following articleTo date the combination of curative surgery and oxaliplatin-based chemotherapy is well recommended as theclassical treatment strategy for stage III colon cancer 1

This article discusses the use of adjuvant chemotherapy in stage III colon cancer patients. The authors highlight two major problems in clinical practice: a significant percentage of patients do not benefit from adjuvant chemotherapy and develop postoperative metastases, and chemotherapy-related toxicity often prevents patients from completing the entire planned duration of treatment. The International Duration Evaluation of Adjuvant Therapy (IDEA) trial introduced risk definitions for stage III colon cancer to guide the duration of adjuvant chemotherapy. However, the TNM stage alone is insufficient to determine which patients will benefit from chemotherapy. The study aims to determine the prognostic effect of lymphovascular invasion (LVI) and perineural invasion (PNI) in stage III colon cancer patients and identify the specific group of patients who could benefit from a total duration of adjuvant chemotherapy based on the presence of LVI and PNI. The study included 402 patients with stage III colon cancer who underwent primary tumor resection and adjuvant chemotherapy. The results of the study will contribute to the development of personalized treatment strategies for stage III colon cancer patients